Biopharma / Medtech Reports

May 7, 2025

Rx Most Favored Nation (MFN) Estimates

•

John Leppard

ABBV (US), AMGN (US), GILD (US)
May 1, 2025

GKOS: iDose & iStent Policy Landscape

•

John Leppard

GKOS (US)
April 29, 2025

[EXAS] Screening Uncertainty Post-SCOTUS?

•

John Leppard

EXAS (US), GH (US)
April 21, 2025

Diagnostics: Supreme Court Quick Takes

•

John Leppard

EXAS (US), GH (US), HOLX (US), MYGN (US), NEO (US)
April 21, 2025

Diagnostics & Supreme Court Expectations

•

John Leppard

EXAS (US), GH (US), HOLX (US), MYGN (US), NEO (US), OSUR (US)
April 17, 2025

Rx Executive Order: Style of Substance

•

John Leppard
April 17, 2025

Life Science Tools: NIH Headwinds & Congressional Guardrails

•

John Leppard

A (US), AVTR (US), BRKR (US), ILMN (US), MTD (US), TMO (US)
April 15, 2025

Rx Tariff Timing & Supply Chain Implications

•

John Leppard
April 14, 2025

Medtech & Medicare Inpatient Implications

•

John Leppard

ABT (US), BSX (US), DXCM (US), EW (US), MMSI (US), SIBN (US)
April 4, 2025

[NVO, LLY] No Medicare / Medicaid Coverage for Obesity Drugs

•

John Leppard

LLY (US), NVO (US)